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Abstract
Sepsis is one of the most common conditions encountered in the
intensive care unit and is the 10th leading cause of death overall in
the United States. Both long-term survival and health-related
quality of life are reduced in survivors of sepsis, yet there is little
knowledge of the effect of sepsis-specific interventions on either
long-term survival or health-related quality of life. The present
article discusses the importance of studying health-related quality
of life as it relates to sepsis management strategies, particularly in
the context of pharmacologic therapy with recombinant human
activated protein C.
Sepsis affects more than 750,000 patients each year in the
United States; it is the 10th leading cause of death and one
of the leading causes for admission to the intensive care unit
[1-4]. The estimated mortality from sepsis is 20–30%,
meaning that approximately 500,000 patients survive their
septic episode annually in the United States alone [3,4].
What happens to these sepsis survivors? Are they able to
resume their lives and regular activities, or does sepsis have
far-reaching effects that extend beyond the hospitalization?
Ten years ago, Quartin and colleagues were the first to show
that sepsis has long-lasting effects and increases the risk of
death up to 5 years after hospitalization for the septic episode
[5]. Mounting evidence has since demonstrated that survivors
of sepsis have a higher long-term risk of death and a lower
health-related quality of life (HRQoL) when compared with
the general population [6-8].
In 2001, recombinant human activated protein C (rhAPC)
was shown to significantly reduce the 28-day mortality in
patients with severe sepsis [9]. A subgroup analysis demon-
strated that patients who were more severely ill, with multiple
organ dysfunction or with Acute Physiology and Chronic
Health Evaluation (APACHE) II scores ≥25, accrued the
greatest benefit from rhAPC, resulting in drug approval
focused on these sepsis populations [10]. A subsequent
randomized controlled trial that evaluated rhAPC use in
patients with severe sepsis and a low risk of death (APACHE
II score <25) found no survival benefit with rhAPC [11].
Given the high cost of rhAPC, the attendant bleeding risk
associated with its use, and the lack of clinical trials
confirming its efficacy, there continues to be debate and
controversy regarding its appropriate use [12].
With the increasing emphasis on patient-centered outcomes
in clinical trials, we are now more frequently assessing short-
term and long-term survival and, at least sometimes, HRQoL.
In assessing long-term outcomes among sepsis survivors
from the original rhAPC trial, the short-term survival benefit for
more severely ill patients (APACHE II scores ≥25) treated
with rhAPC was also evident at 3, 6 and 12 months, while
there was no difference in survival for those less severely ill
patients [8].
In the previous issue of Critical Care, Longo and colleagues
evaluated the effect of rhAPC on long-term HRQoL and
resource utilization in patients with severe sepsis [1]. Using an
observational cohort of 100 patients with severe sepsis (36
patients received rhAPC and 64 patients received standard
care) who survived to day 28, the patients’ HRQoL was
measured using the Short Form 36 (SF-36) at 3, 5 and
7 months, and resource utilization was measured using
patients’ self-reports recorded in a diary. Patients who were
treated with rhAPC had significantly better physical
component scores on the SF-36 throughout the follow-up
period, without significant differences in other components of
the SF-36. Patients treated with rhAPC also had a significantly
shorter hospital stay compared with patients in the standard
care group, and showed statistically nonsignificant improve-
ments in the rate of return to employment.
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One of the major limitations of their study is that rhAPC was
administered in a nonrandomized fashion, meaning the use of
rhAPC was left to the discretion of the attending physician.
Unfortunately, we are given little information about what
factors the attending physicians considered when deciding to
treat patients with rhAPC. Without the design of a
randomized controlled trial, the results are subject to bias and
confounding by unmeasured factors. The authors recognize
these limitations and demonstrated that the two groups of
patients (rhAPC vs. standard care) were similar in illness
severity (APACHE II score) and had similar numbers of
comorbidities. However, patients who received rhAPC were
significantly younger and more likely to have been admitted
through the emergency department. These dissimilarities
suggest that there may have been other important
unmeasured differences between groups. Further, there are
no data provided about other factors that may have
influenced survival and HRQoL such as the type or severity of
comorbities (HIV, malignancy) [13-15], organ dysfunction
[2,3], use of vasopressors or need for mechanical ventilation.
These unmeasured differences may fully or partially account
for the observed differences in long-term HRQoL. For
example, younger patients with minor comorbidities (for
example, hypertension) and a better chance of long-term
survival may have been more likely to receive rhAPC than an
elderly patient with metastatic cancer. Other limitations
include the small sample size and the limited power to detect
smaller but meaningful differences in other components of
the SF-36 or resource utilization.
Despite the limitations of the study, Longo and colleagues
address an important issue – evaluating the long-term effects
of a sepsis therapy. Their findings suggest that treatment with
rhAPC may result in improved long-term physical functioning
in patients with severe sepsis. The authors hypothesize that
rhAPC may reduce acute organ dysfunction, thereby
diminishing the likelihood of chronic dysfunction and thus
improving long-term HRQoL. As noted by the authors, this
study does not provide conclusive evidence that rhAPC
improves long-term HRQoL, and nor does this study provide
any insight into the mechanisms responsible for the
improvement in physical functioning. Instead, the study offers
intriguing preliminary data that should provide the foundation
for a larger, more rigorously designed clinical trial examining
the long-term effects of rhAPC on HRQoL. Certainly, if
rhAPC is shown to improve long-term health outcomes,
including HRQoL, it will open new windows for drug
evaluation and provide more evidence to help us determine
the optimal use of this controversial medication.
Competing interests
The authors declare that they have no competing interests.
References
1.  Longo CJ, Heyland DK, Fisher HN, Fowler RA, Martin CM, Day
AG: A long-term follow-up study investigating health-related
quality of life and resource use in survivors of severe sepsis:
comparison of recombinant human activated protein C with
standard care. Crit Care 2007, 11:R128.
2.  Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J,
Pinsky MR: Epidemiology of severe sepsis in the United
States: analysis of incidence, outcome, and associated costs
of care. Crit Care Med 2001, 29:1303-1310.
3.  Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of
sepsis in the United States from 1979 through 2000. N Engl J
Med 2003, 348:1546-1554.
4.  Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K:
Epidemiology of severe sepsis occurring in the first 24 hrs in
intensive care units in England, Wales, and Northern Ireland.
Crit Care Med 2003, 31:2332-2338.
5.  Quartin AA, Schein RM, Kett DH, Peduzzi PN: Magnitude and
duration of the effect of sepsis on survival. Department of
Veterans Affairs Systemic Sepsis Cooperative Studies Group.
JAMA 1997, 277:1058-1063.
6.  Perl TM, Dvorak L, Hwang T, Wenzel RP: Long-term survival and
function after suspected gram-negative sepsis. JAMA 1995,
274:338-345.
7.  Heyland DK, Hopman W, Coo H, Tranmer J, McColl MA: Long-
term health-related quality of life in survivors of sepsis. Short
Form 36: a valid and reliable measure of health-related quality
of life. Crit Care Med 2000, 28:3599-3605.
8.  Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R,
Weissfeld LA, Bernard GR: The effect of drotrecogin alfa (acti-
vated) on long-term survival after severe sepsis. Crit Care
Med 2004, 32:2199-2206.
9.  Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF,
Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely
EW, et al.: Efficacy and safety of recombinant human activated
protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
10.  Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut
JF, Vincent JL, Macias WL, Bernard GR: Drotrecogin alfa (acti-
vated) administration across clinically important subgroups of
patients with severe sepsis. Crit Care Med 2003, 31:12-19.
11.  Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL,
Francois B, Guy JS, Bruckmann M, Rea-Neto A, et al.: Drotreco-
gin alfa (activated) for adults with severe sepsis and a low
risk of death. N Engl J Med 2005, 353:1332-1341.
12.  Friedrich JO, Adhikari NK, Meade MO: Drotrecogin alfa (acti-
vated): does current evidence support treatment for any
patients with severe sepsis? Crit Care 2006, 10:145.
13.  Mrus JM, Braun L, Yi MS, Linde-Zwirble WT, Johnston JA: Impact
of HIV/AIDS on care and outcomes of severe sepsis. Crit
Care 2005, 9:R623-R630.
14.  Danai PA, Moss M, Mannino DM, Martin GS: The epidemiology
of sepsis in patients with malignancy. Chest 2006, 129:1432-
1440.
15.  Esper AM, Moss M, Lewis CA, Nisbet R, Mannino DM, Martin GS:
The role of infection and comorbidity: factors that influence
disparities in sepsis. Crit Care Med 2006, 34:2576-2582.